VMD clarifies MRL for Altrenogest
The Veterinary Medicines Directorate (VMD) have revised the maximum residue limit (MRL) for Altrenogest, a hormone used in commercial equine breeding, after careful consideration of the relevant scientific data. The revised MRL is higher than was previously the case, although it has been deemed necessary that existing residue studies will need to be re-examined. Also, it is likely that the withdrawal periods of relevant products across the EU will be set to a limit of 15 days by a European Council Directive.
The process to establish the revised withdrawal periods has started, and is currently being co-ordinated across the European Union. It is hoped that all new batches of Altrenogest-containing products intended for the UK market will specify the shorter withdrawal periods by the end of 2012. In the meantime, these products can remain on the market.
Eligible members of BEVA will be able to vote for their Council team until Monday, 17 August 2026. Members will have received an election email on 17 July.
